Nordstjernan is investing in Ascilion, a Swedish medtech company founded in 2012 and based in Stockholm, Sweden.
Ascilion has developed and patented a technology that uses an array of hollow microneedles to extract the interstitial fluid (ISF) that surrounds the body’s cells and that is a good carrier of biomarkers.
In recent years, Nordstjernan has invested actively in the health sector, and the firm’s holdings in this sector currently account for nearly 25 per cent of net asset value.
The parties have agreed not to disclose the terms of the transaction.
